Improved FLT3 Internal Tandem Duplication PCR Assay Predicts Outcome after Allogeneic Transplant for Acute Myeloid Leukemia

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 12, 2014, Pages 1989-1995

  Grunwald, Michael R ^a   Tseng, Li Hui ^b,c   Lin, Ming Tseh ^c   Pratz, Keith W ^d   Eshleman, James R ^c   Levis, Mark J ^d   Gocke, Christopher D ^c,d  

^a LEVINE CANCER INSTITUTE   (United States)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Acute myeloid leukemia (AML); Bone marrow transplant; FLT3; Internal tandem duplication(ITD); Minimal residual disease(MRD); Tandem duplication PCR(TD PCR)

Indexed keywords

BUSULFAN; CD135 ANTIGEN; CYCLOPHOSPHAMIDE; FLUDARABINE; FLT3 PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOTRANSPLANTATION; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE DUPLICATION; GENE MUTATION; GENETIC PARAMETERS; HUMAN; INTERNAL TANDEM DUPLICATION; MALE; MYELOABLATIVE CONDITIONING; POLYMERASE CHAIN REACTION; PREDICTION; RECURRENCE FREE SURVIVAL; TREATMENT OUTCOME; ALLOGRAFT; BLOOD; GENE EXPRESSION REGULATION; GENETICS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; NUCLEOTIDE SEQUENCE; PREDICTIVE VALUE; RECURRENT DISEASE; STEM CELL TRANSPLANTATION;

ADULT; ALLOGRAFTS; DNA MUTATIONAL ANALYSIS; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTAGENESIS, INSERTIONAL; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; RECURRENCE; STEM CELL TRANSPLANTATION;

EID: 84912080352     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.08.015     Document Type: Article

References (28)

1. Marcucci G., Maharry K., Radmacher M.D., et al. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B. Study. J Clin Oncol 2008, 26:5078-5087.
2. Schlenk R.F., Dohner K., Krauter J., et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. NEngl J Med 2008, 358:1909-1918.
3. Levis M., Small D. FLT3: ITDoes matter in leukemia. Leukemia 2003, 17:1738-1752.
4. Nakao M., Yokota S., Iwai T., et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996, 10:1911-1918.
5. DeZern A.E., Sung A., Kim S., et al. Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution. Biol Blood Marrow Transplant 2011, 17:1404-1409.
6. Kayser S., Döhner K., Krauter J., et al. Impact of allogeneic transplantation from matched related and unrelated donors on clinical outcome in younger adult AML patients with FLT3 internal tandem duplications. Blood 2010, 116. abstract 909.
7. Bornhauser M., Illmer T., Schaich M., et al. Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML. Blood 2007, 109:2264-2265.
8. Sengsayadeth S.M., Jagasia M., Engelhardt B.G., et al. Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers. Bone Marrow Transplant 2012, 47:1535-1537.
9. Gale R.E., Hills R., Kottaridis P.D., et al. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood 2005, 106:3658-3665.
10. Brunet S., Labopin M., Esteve J., et al. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. JClin Oncol 2012, 30:735-741.
11. Cheson B.D., Bennett J.M., Kopecky K.J., et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. JClin Oncol 2003, 21:4642-4649.
12. Nazha A., Cortes J., Faderl S., et al. Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia. Haematologica 2012, 97:1242-1245.
13. Murphy K.M., Levis M., Hafez M.J., et al. Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. JMol Diagn 2003, 5:96-102.
14. Thiede C., Steudel C., Mohr B., et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002, 99:4326-4335.
15. Kiyoi H., Towatari M., Yokota S., et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 1998, 12:1333-1337.
16. Walter R.B., Gooley T.A., Wood B.L., et al. Impact of pre-transplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. JClin Oncol 2011, 29:1190-1197.
17. Yin J.A., O'Brien M.A., Hills R.K., et al. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood 2012, 120:2826-2835.
18. Kronke J., Schlenk R.F., Jensen K.O., et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. JClin Oncol 2011, 29:2709-2716.
19. Schiller J., Praulich I., Krings Rocha C., Kreuzer K.A. Patient-specific analysis of FLT3 internal tandem duplications for the prognostication and monitoring of acute myeloid leukemia. Eur J Haematol 2012, 89:53-62.
20. Abdelhamid E., Preudhomme C., Helevaut N., et al. Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia. Leuk Res 2012, 36:316-323.
21. Scholl S., Loncarevic I.F., Krause C., et al. Analyses of minimal residual disease based on Flt3 mutations in allogeneic peripheral blood stem cell transplantation. JCancer Res Clin Oncol 2005, 131:279-283.
22. Scholl S., Loncarevic I.F., Krause C., et al. Minimal residual disease based on patient specific Flt3-ITD and -ITT mutations in acute myeloid leukemia. Leuk Res 2005, 29:849-853.
23. Lin M.T., Tseng L.H., Beierl K., et al. Tandem duplication PCR: An ultrasensitive assay for the detection of internal tandem duplications of the FLT3 gene. Diagn Mol Pathol 2013, 22:149-155.
24. Nakano Y., Kiyoi H., Miyawaki S., et al. Molecular evolution of acute myeloid leukaemia in relapse: unstable N-ras and FLT3 genes compared with p53 gene. Br J Haematol 1999, 104:659-664.
25. Kottaridis P.D., Gale R.E., Langabeer S.E., et al. Studies of FLT3 mutations inpaired presentation and relapse samples from patients with acutemyeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood 2002, 100:2393-2398.
26. Shih L.Y., Huang C.F., Wu J.H., et al. Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood 2002, 100:2387-2392.
27. Metzelder S.K., Schroeder T., Finck A., et al. High activity of sorafenib inFLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia 2012, 26:2353-2359.
28. Sharma M., Ravandi F., Bayraktar U.D., et al. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. Biol Blood Marrow Transplant 2011, 17:1874-1877.